JAN 09, 2018 06:17 AM PST

Something Else for Beta Blockers to Do: Treat Melanoma

WRITTEN BY: Kara Marker

A drug used to lower blood pressure and prevent heart attacks could also be used to treat melanoma. From Penn State, researchers are studying how a specific type of beta blocker - widely available and approved by the FDA - can improve the effectiveness of cancer immunotherapy for melanoma patients whose cancer has spread to different tissues in the body.

Credit: Penn State / © iStock Photo / digicomphoto

Beta blockers reduce blood pressure by opening up blood vessels to improve blood flow and prevent heart attacks by inhibiting the effects of epinephrine, a hormone also called adrenaline. Pan beta blockers are commonly known to be safe, which means that they could be more quickly applied to melanoma patients than a newly developed drug. In theory, beta blockers are able to lower stress to empower the immune system to fight cancer on its own.

"Most patients are either prescribed beta-1 selective blockers or are not taking beta blockers at all,” explained Dr. Todd Schell. “This means there's a large population of patients who may be eligible to take pan beta blockers while being treated with immunotherapy.”

Metastatic melanoma patients receiving immunotherapy may have the best chance at living longer, although even with the treatment the response rates are low - less than 35 percent. “How can we make these treatments better?” asked Penn State’s Dr. Joseph Drabick.

"Beta blockers slow your heart rhythm, but they can also affect immune cells and improve immune function," Schell said. "We wanted to see if there would be a correlation between the beta blockers patients were taking for another condition and their response to immunotherapy.”

The new Penn State study involved giving beta blockers to melanoma patients receiving cancer immunotherapy as opposed to just immunotherapy. Of 195 metastatic melanoma patients being treated with immunotherapy, 62 were also taking beta blockers. Schell, Drabick, and the other researchers compared survival between patients taking two different kinds of beta blockers, beta 1-selective and pan beta blockers, and patients taking no beta blockers at all.

The results showed that patients taking pan beta blockers were significantly more likely to survive (70 percent alive after five years of immunotherapy) than patients taking beta 1-selective beta blockers or no beta blockers at all (25 percent). Researchers completed virtually the same study again, this time in mice with melanoma. Like the human trial, the mice were receiving immunotherapy with or without additional treatment of pan beta blockers. Immunotherapy plus pan beta blockers delayed tumor growth and increased survival.

“We saw that for patients taking pan beta blockers, there was a dramatic improvement in survival, and we were able to duplicate these findings in mice and see the exact same phenomenon,” Drabick explained.

Going forward, the Penn State researchers will continue their study on using beta blockers to improve immunotherapy to potentially treat a variety of cancers.

The present study was published in the journal OncoImmunology.

Sources: MayoClinic, Penn State

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
SEP 04, 2018
Immunology
SEP 04, 2018
Development of Damaging Immune Cells in Tuberculosis Infection
Development of damaging white blood cells occurs during Tuberculosis infection leading to a maladaptive immune response....
SEP 07, 2018
Health & Medicine
SEP 07, 2018
What's Behind the Massive Measles Outbreak in Europe?
Measles is a disease that many believe was eradicated years ago. That's true, to a point, but like a bad penny, it's back. In the United States, th...
SEP 26, 2018
Neuroscience
SEP 26, 2018
Therapeutic antibodies for Alzheimer's disease: challenges and hopes
Solanezumab: this simple name evokes at the same time one of the greatest hopes and the worst disillusions for Alzheimer’s Disease (AD) patients. Two...
OCT 01, 2018
Immunology
OCT 01, 2018
Transplanting Fecal Matter
A study published in the New England Journal of Medicine provides insight into the effectiveness of a fecal microbiome transplant when compared to antibiotic therapy....
OCT 04, 2018
Videos
OCT 04, 2018
Why Do We Have Nightmares With a Fever?
Fever is the body’s response to a threat. When some viruses or bacteria try to enter the body, an immune response begins that can include a sharp ris...
OCT 14, 2018
Immunology
OCT 14, 2018
Malaria Vesicles Activating Immune Responses
Red blood cells infected with malaria will secrete small vesicles that activate pathogen receptors...
Loading Comments...